Liver Enzyme Monitoring in Patients Treated With Troglitazone
Open Access
- 15 August 2001
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 286 (7), 831-833
- https://doi.org/10.1001/jama.286.7.831
Abstract
Troglitazone is a thiazolidinedione antidiabetic agent that decreases insulin resistance. It was approved by the US Food and Drug Administration (FDA) in January 1997 for treatment of type 2 diabetes mellitus. During premarketing clinical trials, serum liver transaminase elevations exceeding 3 times the upper limit of normal were observed in 1.9% of troglitazone-treated patients vs 0.6% in comparators.1 Of 2510 patients treated with troglitazone in these trials, 2 were hospitalized with drug-associated hepatitis and 2 developed jaundice.Keywords
This publication has 4 references indexed in Scilit:
- An Autopsy Case of Troglitazone-Induced Fulminant HepatitisDiabetes Care, 1998
- Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case ReportAnnals of Internal Medicine, 1998
- The infrequency of liver function testing in patients using nonsteroidal anti-inflammatory drugsArchives of Family Medicine, 1995
- Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United StatesNew England Journal of Medicine, 1993